Tumor-colonizing bacteria: a potential tumor targeting therapy.

Area of Science:

• Oncology
• Microbiology
• Biotechnology

Background:

• Historical observations date back to 1813, noting tumor regression following gas gangrene.
• Numerous studies have explored bacteria as a viable antitumor therapy.
• Specific bacteria like Bifidobacterium and Clostridium have demonstrated tumor-colonizing and tumor-reducing capabilities.

Purpose of the Study:

• To review the advancements in using bacteria for cancer therapy.
• To highlight the potential of genetically engineered bacteria in oncology.
• To assess the safety and efficacy of bacterial-based tumor treatment.

Main Methods:

• Review of historical and recent scientific literature on bacterial antitumor therapy.
• Analysis of studies involving Bifidobacterium and Clostridium in tumor models.
• Examination of research on genetically engineered bacteria for cancer treatment, including suicide genes and cytokine expression.

Main Results:

• Bacteria like Bifidobacterium and Clostridium can selectively colonize tumors and reduce their size.
• Genetic engineering enables bacteria to express therapeutic agents such as pro-drug converting enzymes, cytokines, antibodies, or suicide genes.
• Animal studies using engineered bacteria for tumor treatment have reported minimal side effects.

Conclusions:

• Bacterial-based therapies have evolved significantly from early observations to sophisticated, genetically engineered approaches.
• Engineered bacteria demonstrate potential for targeted cancer treatment with a favorable safety profile in preclinical studies.
• Bacteria represent a promising next-generation therapeutic strategy for cancer treatment.